✦ LIBER ✦

T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study

✍ Scribed by P. Andreone; S. Pol; S. Roberts; Z. Younossi; M. Diago; E.J. Lawitz; R. Focaccia; G.R. Foster; A. Horban; I. Lonjon-Domanec; R. DeMasi; R. Van Heeswijk; S. DeMeyer; G. Picchio; J. Witek; S. Zeuzem

Book ID: 118648282
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 62 KB
Volume: 44
Category: Article
ISSN: 1590-8658
DOI: 10.1016/s1590-8658(12)60064-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

T-26 Impact of anemia and ribavirin dose

T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study

✍ P. Andreone; S. Roberts; S. Pol; Z. Younossi; M. Diago; E.J. Lawitz; R. Focaccia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB

T-29 Predictors of virologic response wi

T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study

✍ P. Andreone; T. Berg; S. Pol; S. Roberts; Z. Younossi; M. Diago; E.J. Lawitz; R. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

T-28 Impact of insulin resistance on vir

T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study

✍ P. Andreone; Z. Younossi; F. Negro; L. Serfaty; S. Pol; M. Diago; S. Zeuzem; E.J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 81 KB

1167 PRE-TREATMENT IP-10 LEVELS AND IL28

1167 PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE REALIZE STUDY

✍ Vijgen, L.; Talloen, W.; Scholliers, A.; Johansson, S.; Tuefferd, M.; De Meyer, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

O10 SAFETY AND EFFICACY OF THE ALL-ORAL

O10 SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY

✍ Hezode, C.; Serfaty, L.; Vierling, J.M.; Kugelmas, M.; Pearlman, B.; Sievert, W. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB